AU2005240096A1 - Human complement C3 derivates with cobra venom factor-like function - Google Patents
Human complement C3 derivates with cobra venom factor-like function Download PDFInfo
- Publication number
- AU2005240096A1 AU2005240096A1 AU2005240096A AU2005240096A AU2005240096A1 AU 2005240096 A1 AU2005240096 A1 AU 2005240096A1 AU 2005240096 A AU2005240096 A AU 2005240096A AU 2005240096 A AU2005240096 A AU 2005240096A AU 2005240096 A1 AU2005240096 A1 AU 2005240096A1
- Authority
- AU
- Australia
- Prior art keywords
- protein
- modified
- cvf
- complement
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 title claims 8
- 239000002642 cobra venom Substances 0.000 title 1
- 101710131943 40S ribosomal protein S3a Proteins 0.000 claims 22
- 238000000034 method Methods 0.000 claims 7
- 102000057770 human C3 Human genes 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 4
- 102000035118 modified proteins Human genes 0.000 claims 4
- 108091005573 modified proteins Proteins 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 101710172562 Cobra venom factor Proteins 0.000 claims 1
- 102000003712 Complement factor B Human genes 0.000 claims 1
- 108090000056 Complement factor B Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000018639 Parkinson disease 20 Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 0 CCCC(CC([C@@](*)[C@](*CC[N+](*)[O-])[C@]1*C1)*=*)** Chemical compound CCCC(CC([C@@](*)[C@](*CC[N+](*)[O-])[C@]1*C1)*=*)** 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56706904P | 2004-04-30 | 2004-04-30 | |
| US60/567,069 | 2004-04-30 | ||
| US65324705P | 2005-02-14 | 2005-02-14 | |
| US60/653,247 | 2005-02-14 | ||
| US66735205P | 2005-03-31 | 2005-03-31 | |
| US60/667,352 | 2005-03-31 | ||
| PCT/US2005/015119 WO2005107785A2 (en) | 2004-04-30 | 2005-04-29 | Human complement c3 derivates with cobra venom factor-like function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2005240096A1 true AU2005240096A1 (en) | 2005-11-17 |
Family
ID=35320733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005240096A Abandoned AU2005240096A1 (en) | 2004-04-30 | 2005-04-29 | Human complement C3 derivates with cobra venom factor-like function |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8632780B2 (enExample) |
| EP (1) | EP1755658A4 (enExample) |
| JP (1) | JP2008502323A (enExample) |
| KR (1) | KR20070036057A (enExample) |
| AU (1) | AU2005240096A1 (enExample) |
| CA (1) | CA2565227A1 (enExample) |
| IL (1) | IL178905A0 (enExample) |
| MX (1) | MXPA06012321A (enExample) |
| WO (1) | WO2005107785A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7553931B2 (en) | 2003-07-03 | 2009-06-30 | Pls-Design Gmbh | Complement depletion using recombinant human C3-derivatives |
| EP1755658A4 (en) | 2004-04-30 | 2008-11-05 | Univ Hawaii | HUMAN COMPLEMENT C3 DERIVATIVES WITH COBRA FACTOR ARTIFICIAL FUNCTION |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| RU2549468C2 (ru) * | 2013-08-09 | 2015-04-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН") | Способ определения стабилизации с3-конвертазы классического пути активации комплемента человека |
| WO2015192101A1 (en) * | 2014-06-12 | 2015-12-17 | University Of Hawaii | Uses of humanized cobra venom factor for reducing or preventing immunogenicity |
| US20190016766A1 (en) * | 2015-10-07 | 2019-01-17 | Daniel E. Benjamin | Use of improved modulators of complement function as cancer therapeutics |
| US11903996B2 (en) * | 2015-10-07 | 2024-02-20 | David C. Fritzinger | Modulators of complement function |
| CN106472359B (zh) * | 2016-10-21 | 2019-07-26 | 新希望六和饲料股份有限公司 | 一种1-3周龄雏鸡用饲料盘 |
| CN106472354B (zh) * | 2016-10-21 | 2019-05-31 | 新希望六和饲料股份有限公司 | 一种成年鸡用饲料盘 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4661347A (en) | 1982-11-12 | 1987-04-28 | Scripps Clinic | Cytotoxic compositions |
| US5714344A (en) | 1993-04-07 | 1998-02-03 | Georgetown University | Protease-derivatized CVF |
| AU695960B2 (en) | 1993-04-07 | 1998-08-27 | Georgetown University | DNA encoding cobra C3, CVF1, and CVF2 |
| SK29697A3 (en) | 1994-09-08 | 1998-01-14 | Imutran Ltd | Modified human c3 proteins |
| US6221657B1 (en) | 1995-09-08 | 2001-04-24 | Imutran Limited | Modified human C3 DNA sequences and vectors |
| US5922320A (en) | 1996-06-14 | 1999-07-13 | Georgetown University | Recombinant proCVF |
| US7553931B2 (en) | 2003-07-03 | 2009-06-30 | Pls-Design Gmbh | Complement depletion using recombinant human C3-derivatives |
| EP1755658A4 (en) | 2004-04-30 | 2008-11-05 | Univ Hawaii | HUMAN COMPLEMENT C3 DERIVATIVES WITH COBRA FACTOR ARTIFICIAL FUNCTION |
| WO2008060634A2 (en) | 2006-11-15 | 2008-05-22 | University Of Hawaii | Human complement c3 derivatives with cobra venom factor-like function |
-
2005
- 2005-04-29 EP EP05743027A patent/EP1755658A4/en not_active Withdrawn
- 2005-04-29 US US11/579,235 patent/US8632780B2/en active Active
- 2005-04-29 JP JP2007511077A patent/JP2008502323A/ja active Pending
- 2005-04-29 KR KR1020067025253A patent/KR20070036057A/ko not_active Ceased
- 2005-04-29 CA CA002565227A patent/CA2565227A1/en not_active Abandoned
- 2005-04-29 AU AU2005240096A patent/AU2005240096A1/en not_active Abandoned
- 2005-04-29 WO PCT/US2005/015119 patent/WO2005107785A2/en not_active Ceased
- 2005-04-29 MX MXPA06012321A patent/MXPA06012321A/es not_active Application Discontinuation
-
2006
- 2006-10-26 IL IL178905A patent/IL178905A0/en unknown
-
2007
- 2007-08-07 US US11/890,900 patent/US20080234191A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8632780B2 (en) | 2014-01-21 |
| WO2005107785A2 (en) | 2005-11-17 |
| JP2008502323A (ja) | 2008-01-31 |
| US20080311132A1 (en) | 2008-12-18 |
| EP1755658A2 (en) | 2007-02-28 |
| US20080234191A1 (en) | 2008-09-25 |
| CA2565227A1 (en) | 2005-11-17 |
| WO2005107785A3 (en) | 2005-12-15 |
| KR20070036057A (ko) | 2007-04-02 |
| IL178905A0 (en) | 2007-03-08 |
| MXPA06012321A (es) | 2007-04-19 |
| EP1755658A4 (en) | 2008-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080234191A1 (en) | Human complement C3 derivates with cobra venom factor-like function | |
| KR100188302B1 (ko) | 활성화피브린용해성과항-혈전성단백질 | |
| EP1346034B1 (en) | VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE | |
| JP4451514B2 (ja) | 血液凝固第ｖｉｉ因子改変体 | |
| AU2011222883B2 (en) | Chimeric inhibitor molecules of complement activation | |
| CN101006175A (zh) | 经修饰的维生素k依赖性多肽 | |
| Zhou et al. | Molecular cloning and functional expression of contortrostatin, a homodimeric disintegrin from southern copperhead snake venom | |
| JPS63503275A (ja) | ファクター８：ｃの製造方法 | |
| KR20110114587A (ko) | 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도 | |
| US20100179092A1 (en) | Human complement c3 derivatives with cobra venom factor-like function | |
| JP4855627B2 (ja) | 医薬用途のためのトロンボモジュリン | |
| JP2003313199A (ja) | コラーゲン誘発血小板凝集抑制剤 | |
| Vogel et al. | Cobra venom factor: the unique component of cobra venom that activates the complement system | |
| RU2186110C2 (ru) | Рекомбинантный белок asp-паллидипин, способ его производства и очистки, вектор, штамм, фармацевтическая композиция | |
| Fritzinger et al. | Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion | |
| EP1088069B1 (en) | Angiostatin-binding protein | |
| JP2001515720A (ja) | β−デフェンシン | |
| JPH08511157A (ja) | Ｘａファクター阻害活性を有する新規ポリペプチド | |
| HU220301B (hu) | Véralvadásgátló protosztómiák (vérszívók) nyálából | |
| US6833437B2 (en) | Complement receptor type 1 (CR1)-like sequences | |
| CN101014362A (zh) | 具眼镜蛇毒因子样功能的人补体c3衍生物 | |
| JPH08510903A (ja) | 蛭ヒルド・メディシナリスの組換えｘａ因子インヒビターの作製 | |
| JP2005518801A (ja) | 組換えプロテインｃバリアント | |
| US7122342B1 (en) | Protease-activated receptor PAR4 (ZCHEMR2) | |
| JPH07242700A (ja) | 新規ポリペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |